
    
      Patients with unresectable hepatic metastases secondary to ocular melanoma will undergo a 60
      minute hyperthermic isolated hepatic perfusion with 1.5mg/kg melphalan followed by up to one
      year of oral temozolomide. Response to treatment, duration of response, patterns of failure,
      survival, and quality of life end-points will be followed.
    
  